This course aims to improve patient care and outcomes through evidence-based discussion of clinical practice guidelines and emerging therapies in order to assess and update current practices to promote earlier diagnosis and treatment of pituitary diseases. The multidisciplinary nature of the course will allow for dissemination of knowledge across the variety of practitioners caring for pituitary patients, and for the patients themselves.

After completion of this didactic and case-based educational activity, participants will be up to date on the latest developments in ongoing basic and translational science as well as the clinical management of patients with pituitary conditions. Participants will be able to review available and emerging medical therapies for Cushing’s and acromegaly, discuss new therapies for aggressive and malignant tumors, understand decision making involved in surgical intervention for pituitary tumors, get an overview on potential surgical complications, describe the role of radiation therapy for pituitary tumors,  review neuro-ophthalmological findings in pituitary disease risks, discuss treatment of immunotherapy-related pituitary dysfunction, and assess advances in neuroimaging and tumor markers that may predict tumor behavior and clinical outcomes.

This course is intended for endocrinologists, neurosurgeons, otolaryngologists, radiation oncologists, neurologists, ophthalmologists, neuro-oncologists, family medicine and internal medicine physicians, physicians in training and other allied health professionals who treat and manage patients with pituitary diseases. We also invite patients with pituitary disease and their caregivers to attend this educational activity and participate in our interactive afternoon breakout sessions.

Request for Case Submissions

There will be a tumor board during the provider/clinical breakout session from 1:30-3:00 pm where attendees and faculty will review cases. Attendees will have an opportunity to submit a case for discussion during the course at registration. In order to prepare your submission, we ask that you provide a BRIEF summary of your case and include key lab results. Please ensure that all identifiable PHI has been removed. Cases should have an educational purpose. The course faculty will not be able to provide a detailed/complex consult review during the course and they will try to get through as many cases as possible.

Patient Breakout Session

We also invite patients with pituitary disease and their caregivers to attend this educational activity and participate in our interactive afternoon breakout sessions. Pituitary patients will be able to review treatment options, learn about ongoing clinical trials, and discuss their comprehensive care with providers and other patients. The educational objective of this patient session is to provide a forum for pituitary patients to discuss treatment options and new therapies with providers and other patients. Please note AMA PRA Category 1 Credits™ will not be offered for the Patient Breakout Session.

1. Review the efficacy and side effect profiles of treatment options, including emerging therapies, for Cushing’s and acromegaly
2. Discuss surgical outcomes and risk management for pituitary and skull base tumors
3. Describe recent advances in pituitary neuropathology and neuroimaging
4. Critically appraise the role of radiation therapy in the management of pituitary tumors
5. Debate treatment decisions supporting the use and timing of new therapies for aggressive and malignant pituitary tumors
6. Provide a forum for pituitary patients to discuss treatment options and new therapies with providers and other patients

Patient Registration Coming Soon!
We are currently finalizing the patient sessions of this program. If you are a patient interested in attending this program, click here to sign up for announcements. We will email you as soon as registration is available for patients

--

Course registration includes continental breakfast, lunch, and refreshment breaks. Please contact cme@mskcc.org at least one week prior to the course if you have any special dietary requests or require any specific accommodations.

*Early Registration expires February 15, 2019
**Industry professionals may attend MSK CME activities for their own education. Marketing, sales, and promotion of products and services is strictly prohibited at MSK CME activities.

Registration Discounts/Promotions

• MSK CME offers a 30% discounted rate for MSK Alumni, MSK Cancer Alliance and Cancer Care Partners. If you are a member of one of these groups, please contact cme@mskcc.org for more information.
• MSK employee registration is complimentary. However, you must complete course registration in order to attend this course.

Please note: after your payment has been processed, no further promotional discount adjustments will be made to your registration.

Cancellation Policy

If you cancel your participation in this course, your registration fee, less a $75 administrative fee, will be refunded when email notification is received by the MSK Office of Continuing Medical Education (MSK CME) at least 7 days prior to the first day of the course (cme@mskcc.org).

Cancellations or no-shows after this date are not eligible for a refund. MSK CME reserves the right to cancel or postpone any course due to unforeseen circumstances. In the unlikely event we must cancel or postpone this course, we will refund the registration fee in full, but are not responsible for any related costs, charges, or expenses to participants, including fees incurred by airline/travel/lodging agencies. At any time, you may substitute another registrant in your place after contacting MSK CME with the relevant information.

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of 6.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Endorsed by the Pituitary Network Association (PNA) and Cushing’s Support & Research Foundation (CSRF).

MSK Course Directors

Viviane Tabar, MD
Chair, Department of Neurosurgery
Theresa Feng Chair in Neurosurgical Oncology
Department of Neurosurgery

Eliza B. Geer, MD
Medical Director, Pituitary & Skull Base Tumor Center
Associate Attending
Endocrinology Service
Department of Medicine

Marc A. Cohen, MD, MPH
Surgical Director, Pituitary & Skull Base Tumor Center
Associate Attending
Head and Neck Service
Department of Surgery

Invited Keynote Speaker

Shlomo Melmed, MB, ChB
Executive Vice President of Academic Affairs
Dean of the Medical Faculty and Professor of Medicine
Cedars-Sinai Medical Center

Invited Course Faculty

Marc J. Dinkin, MD 
Director of Neuro-Ophthalmology
Associate Professor 
Departments of Ophthalmology and Neurology
Weill Cornell Medical College
NY Presbyterian Hospital

MSK Course Faculty

Andrew Lin, MD
Assistant Attending
Brain Tumor Service
Department of Neurology

Kathryn Beal, MD
Associate Attending
External Beam Radiotherapy Service,
Brachytherapy Service
Department of Radiation Oncology

Amy Robin Deipolyi, MD, PhD
Assistant Attending
Interventional Radiology Service
Department of Radiology

Monica Girotra, MD
Associate Attending
Endocrinology Service
Department of Medicine

Marc K. Rosenblum, MD
Chief, Autopsy Service
Director, Neuropathology
Founder’s Chair
Department of Pathology

Sasan Karimi, MD
Director, MSKCC 55th Street Radiology
Associate Attending
Neuroradiology Service
Department of Radiology